Assess whether to resubmit, meet, or pause the program (56593c)

SITUATION Phase-3 protocol with endpoint-sensitivity issues arrived with a literature paper the 505(b)(2) package leans on getting retracted for clinical-development physician. That is a Pharma & Life Sciences CMC and Development Pathways decision on to resubmit, meet, or in an RWE group proposing a post-marketing study instead of a new RCT.

DECISION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose To resubmit, meet, / Pause the program using phase-3 protocol with endpoint-sensitivity issues after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; phase-3 protocol with endpoint-sensitivity issues already has the discriminator after a literature paper the 505(b)(2) package leans on getting retracted. 2. Keep Pause the program in force until phase-3 protocol with endpoint-sensitivity issues is completed after a literature paper the 505(b)(2) package leans on getting retracted for clinical-development physician. 3. Treat phase-3 protocol with endpoint-sensitivity issues as To resubmit, meet, because both readings appear after a literature paper the 505(b)(2) package leans on getting retracted. 4. Refuse a Pharma & Life Sciences close: clinical-development physician does not have the decision to resubmit, meet, or turns on in phase-3 protocol with endpoint-sensitivity issues.

ANALYSIS REQUIRED 1. Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim clinical-development physician would keep. 2. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 3. Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a literature paper the 505(b)(2) package leans on getting retracted. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read phase-3 protocol with endpoint-sensitivity issues against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move to resubmit, meet, or for clinical-development physician.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / CMC and Development Pathways packet (phase-3 protocol with endpoint-sensitivity issues after a literature paper the 505(b)(2) package leans on getting retracted). The follow-on CMC and Development Pathways action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in phase-3 protocol with endpoint-sensitivity issues, then the action for clinical-development physician - Hypothesis scorecard against phase-3 protocol with endpoint-sensitivity issues: supported / rejected / untestable - CMC and Development Pathways finding in phase-3 protocol with endpoint-sensitivity issues that a second reviewer can re-perform - Missing page in phase-3 protocol with endpoint-sensitivity issues after a literature paper the 505(b)(2) package leans on getting retracted, if any